Our top pick for
Kadmon Holdings, Inc is a biotechnology business based in the US. Kadmon shares (KDMN) are listed on the NASDAQ and all prices are listed in US Dollars. Kadmon employs 115 staff and has a trailing 12-month revenue of around USD$12.1 million.
|Latest market close||USD$4.34|
|52-week range||USD$2.3 - USD$5.5|
|50-day moving average||USD$4.0718|
|200-day moving average||USD$4.1587|
|Wall St. target price||USD$12.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.372|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||9.60%|
|1 month (2020-12-17)||-3.13%|
|3 months (2020-10-15)||5.34%|
|6 months (2020-07-15)||-0.46%|
|1 year (2020-01-15)||0.93%|
|2 years (2019-01-15)||78.60%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$12.1 million|
|Gross profit TTM||USD$3.8 million|
|Return on assets TTM||-32.37%|
|Return on equity TTM||-83.78%|
|Market capitalisation||USD$756.4 million|
TTM: trailing 12 months
There are currently 29.5 million Kadmon shares held short by investors – that's known as Kadmon's "short interest". This figure is 4.1% down from 30.7 million last month.
There are a few different ways that this level of interest in shorting Kadmon shares can be evaluated.
Kadmon's "short interest ratio" (SIR) is the quantity of Kadmon shares currently shorted divided by the average quantity of Kadmon shares traded daily (recently around 2.5 million). Kadmon's SIR currently stands at 11.71. In other words for every 100,000 Kadmon shares traded daily on the market, roughly 11710 shares are currently held short.
However Kadmon's short interest can also be evaluated against the total number of Kadmon shares, or, against the total number of tradable Kadmon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kadmon's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Kadmon shares in existence, roughly 160 shares are currently held short) or 0.1614% of the tradable shares (for every 100,000 tradable Kadmon shares, roughly 161 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kadmon.
Find out more about how you can short Kadmon stock.
We're not expecting Kadmon to pay a dividend over the next 12 months.
Over the last 12 months, Kadmon's shares have ranged in value from as little as $2.3 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kadmon's is 1.6954. This would suggest that Kadmon's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.